Status:
UNKNOWN
The 90% Effective Dose of Nalbuphine in Mechanical Ventilated Patients in the ICU
Lead Sponsor:
Hua-Qing Shu
Conditions:
Pain
Eligibility:
All Genders
18-80 years
Phase:
PHASE4
Brief Summary
The aim of this study is to determine the effective nalbuphine dose in 90% of intubated patients in the ICU, including the continuous infusion dose and a bolus dose during moving to the lateral decubi...
Detailed Description
The continuous nalbuphine infusion dose starts at 100ug/kg/h, if the BPS scores reaches 3-4, the continuous infusion dose would be decreased by 20 ug/kg/h for next patients. If not, increased by 20 ug...
Eligibility Criteria
Inclusion
- Mechanical invasive ventilation
- Sedated only with nalbuphine
Exclusion
- Pregnant or breast-feeding woman
- Age below 18 or over 80 years
- An indication for deep sedation (e.g.the initial stage of septic shock, acute brain injury or acute respiratory distress syndrome)
- Renal dialysis
- The inability to assess pain by the BPS scale (e.g. paralysis)
- BMI less than 18 or more than 35
- Preadmission use of opioid analgesic for chronic pain
- Severe hepatic failure
- State of consciousness with impossibility to use self-assessment scale; monoamine oxidase inhibitors
Key Trial Info
Start Date :
October 24 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2019
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT03786887
Start Date
October 24 2018
End Date
October 1 2019
Last Update
December 26 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Critical Care Medicine, Union Hospital, Wuhan
Wuhan, China